Nuvectis Pharma (NVCT) Income towards Parent Company (2021 - 2026)

Nuvectis Pharma has reported Income towards Parent Company for 6 years, with the latest figure at -$7.1 million in Q1 2026.

• Quarterly Income towards Parent Company changed 0.11% year-over-year to -$7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$30.8 million (up 27.89% YoY) and the FY2025 annual result came in at -$27.5 million, up 28.69% from the prior year.
• Income towards Parent Company climbed to -$7.1 million in Q1 2026 per NVCT's latest filing, from -$8.3 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$3.9 million in Q1 2022 and troughed at -$25.8 million in Q4 2024.
• A 5-year average of -$11.0 million and a median of -$8.3 million in 2025 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2023 and 2024: Income towards Parent Company tumbled 303.28% in 2023, then jumped 73.86% in 2024.
• Over 5 years, Income towards Parent Company stood at -$15.3 million in 2022, then tumbled by 38.27% to -$21.1 million in 2023, then dropped by 22.09% to -$25.8 million in 2024, then jumped by 67.62% to -$8.3 million in 2025, then rose by 14.39% to -$7.1 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$7.1 million, -$8.3 million, and -$8.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.